On-Demand Webinar | Emerging trends in the expanded use of RWE across the life sciences industry. Where is the industry going?

Recorded on: October 22, 2020

 

Real-world evidence (RWE) has the potential to transform how medicines are discovered, developed, commercialized and reimbursed. Given the opportunity RWE presents, it is now being viewed as a highly strategic capability for the life sciences industry. This Interactive panel discussion featuring leaders from across the life sciences industry will discuss emerging trends in the use of RWE, challenges in realizing the full potential, technology trends and strategic investments.

SPEAKER BIOGRAPHIES

Jeffrey Morgan
Managing Director, Life Sciences, Deloitte

Jeffrey is a Managing Director in Deloitte Consulting’s life sciences practice with 18+ years of relevant LS experience spanning pharmaceuticals, medical devices and consulting. He has significant experience helping clients apply real-world data (RWD) across the product life cycle from R&D through commercialization. Jeffrey has deep knowledge of emerging use cases for RWD and the evolving real-world data landscape. His work has spanned helping clients design enterprise RWE strategies, developing new operating models for leveraging RWD, implementing end to end evidence analytics platforms, custom applications development, defining governance and designing new partnership models within the healthcare ecosystem. He is also the leader of Deloitte’s value-based contracting services and solutions for the life sciences industry.

Nirosha Mahendraratnam Lederer, PhD, MSPH
Managing Associate, Real World Evidence, Duke-Margolis Center for Health Policy, Duke University

Nirosha Mahendraratnam Lederer, PhD MSPH is a Managing Associate at the Duke-Margolis Center for Health Policy, where she helps lead the Center’s real-world evidence (RWE) portfolio. Immediately prior, she was a Subject Matter Expert in the Oncology Center of Excellence at FDA. While there, she helped implement patient-focused drug development in cancer products including clinical trial study design and product review, as well as foster consensus across US and ex-US healthcare stakeholders on best practices for patient-reported outcome capture, analysis, and communication.

Dr. Lederer has over a decade of pharmaceutical policy and health economics and outcomes research experiences including providing evidence-generation advisory services at Avalere Health, working in commercial and medical roles at Genentech and Bristol-Myers Squibb, respectively, and serving on Capitol Hill during the passage of the Affordable Care Act. She received her PhD in Health Outcomes and Policy from the UNC Chapel Hill with a focus on large database analyses and decision-sciences. She received her MSPH in Health Policy & Management from the Johns Hopkins Bloomberg School of Public Health and BA in Public Health from the Johns Hopkins University.

Christopher P. Boone, PhD, FACHE, FHIMSS
Vice President, Global Head of Health Economics and Outcomes Research, AbbVie

Christopher Boone, PhD has a career-long history as a dynamic, innovative thought leader and a public voice on the power of real-world evidence, health informatics, and big data analytics and its ability to radically transform the global health care system into a learning health system.

Chris currently serves as the Vice President, Global Head of Health Economics and Outcomes Research at AbbVie. He is also an adjunct assistant professor of health administration at the New York University's Robert F. Wagner Graduate School of Public Service, an active board member of several influential organizations, and a co-founder of a few start-up companies. Most recently, he served as the vice president and head of global medical epidemiology and big data analysis at Pfizer.

Chris has been recognized as a 2019 Top 100 Innovator in Data & Analytics, a 2018 Emerging Pharma Leader by Pharmaceutical Executive, and a 2017 Top 40 Under 40 Leader in Minority Health by the National Minority Quality Forum (NMQF).

Boone holds, or has held, appointments to some of the most influential national committees focused on health data and patient centricity, including the Board of Directors for the Stewards of Change Institute, the Executive Board of Directors for the Patient Advocate Foundation, the Executive Board of Directors for the National Patient Advocate Foundation, the Board of Directors for SHARE for Cures, the Robert Wood Johnson Foundation’s Data Across Sectors for Health (DASH) Initiative, the Interoperability Committee for the National Quality Forum, the National Committee on Vital and Health Statistics (NCVHS) Working Group on HHS Data Access and Use, the Health IT Policy Committee (federal advisory committee), and the advisory group for the American Society of Clinical Oncologists’ (ASCO) CancerLinQ initiative.

Chris earned a BS from the University of Tulsa, a MHA from the University of Texas at Arlington, a PhD from the University of Texas at Dallas, and two executive certificates from the Harvard Kennedy School. He is a Fellow of the American College of Health Executives and a Fellow of the Healthcare Information Management & Systems Society.

Patrick Loerch
Senior Vice President, Data Science and Biometrics, Gilead

Patrick Loerch has over 20 years of experience in data sciences, real world evidence and genomics research spanning all phases of R&D within the pharmaceutical industry. Dr Loerch currently serves as Senior Vice President, Data Sciences and Biometrics at Gilead Sciences. In addition to oversight of the existing Biometrics and Epidemiology organizations, Dr. Loerch is accountable for the build out and integration of Real World Evidence and Data Sciences capabilities to accelerate the discovery, development and delivery of new medicines. Dr. Loerch’s prior roles include leadership positions at Johnson & Johnson, Celgene and Merck. He began his career at Rosetta Inpharmatics, a genomics start-up in Seattle, WA that was later acquired by Merck. Dr. Loerch received his PhD in Biostatistics from the Harvard University and his BS in Biochemistry from Washington State University.



Sponsor: